Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain Stimulation

NCT: NCT05933681 · ACTIVE_NOT_RECRUITING

NCT IDNCT05933681
StatusACTIVE_NOT_RECRUITING
Start Date2023-07-06
Completion2027-05
SponsorVanderbilt University Medical Center (OTHER)
First posted
Last updated

Brief Summary

The study aims to investigate cognitive impairment associated with Deep Brain Stimulation (DBS) in Parkinson's Disease patients, with a focus on identifying neurophysiology biomarkers of DBS associated cognitive changes. Using neurophysiology data recorded during DBS surgeries and post-implantation, the research intends to identify biomarkers in order to optimize electrode placement, enhance programming, and ultimately minimize DBS-related cognitive side effects.

Frequently Asked Questions

What is Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain Stimulation?

Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain Stimulation is a clinical trial registered under NCT05933681. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05933681?

The current status of NCT05933681 (Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain Stimulation) is: ACTIVE_NOT_RECRUITING.

When did Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain Stimulation start?

Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain Stimulation started on 2023-07-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.